Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.
| Status: | Recruiting |
|---|---|
| Conditions: | Schizophrenia |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 5/23/2018 |
| Start Date: | July 2014 |
| End Date: | December 2020 |
| Contact: | Jo Talledo, B.A. |
| Email: | atalledo@ucsd.edu |
| Phone: | 619-543-3093 |
Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis
This application seeks renewed support for MH59803, "Dopaminergic substrates of startle
gating across species," to extend a clear path of "bench-to-bedside" progress towards a
critical paradigm shift in therapeutic models for schizophrenia (SZ) and schizoaffective
disorder, depressed type (SZA): the use of Pharmacologic Augmentation of Cognitive Therapies
(PACTs). This novel therapeutic strategy for SZ/SZA directly addresses the need for more
effective treatments for this devastating disorder. MH59803 has investigated the neural
regulation of laboratory-based measures of deficient information processing in SZ/SZA
patients, using rodents and healthy human subjects (HS) to explicate the biology of these
deficits, and to establish a rational basis for developing novel therapies for SZ/SZA. In its
first 9 years, MH59803 studies of the neural regulation of prepulse inhibition (PPI) of
startle in rats focused on basic neurobiological and molecular mechanisms. Over the past 2
years of support, MH59803 studies moved "from bench-to-bedside," focusing on dopamine (DA)
agonist effects on PPI and neurocognition in HS, and their regulation by genes identified in
cross-species studies. These studies detected biological markers that predict PPI-enhancing
and pro-cognitive effects of the DA releaser, amphetamine (AMPH) in humans, leading to
specific predictions of AMPH effects on PPI, neurocognition and Targeted Cognitive Training
in SZ/SZA patients. If confirmed in the present application, these predictions could help
transform therapeutic approaches to SZ/SZA. This renewal application of MH59803 thus reflects
a logical progression of studies at systems and molecular levels, translated first to HS, and
now to potentially transformative therapeutic models in SZ/SZA patients.
gating across species," to extend a clear path of "bench-to-bedside" progress towards a
critical paradigm shift in therapeutic models for schizophrenia (SZ) and schizoaffective
disorder, depressed type (SZA): the use of Pharmacologic Augmentation of Cognitive Therapies
(PACTs). This novel therapeutic strategy for SZ/SZA directly addresses the need for more
effective treatments for this devastating disorder. MH59803 has investigated the neural
regulation of laboratory-based measures of deficient information processing in SZ/SZA
patients, using rodents and healthy human subjects (HS) to explicate the biology of these
deficits, and to establish a rational basis for developing novel therapies for SZ/SZA. In its
first 9 years, MH59803 studies of the neural regulation of prepulse inhibition (PPI) of
startle in rats focused on basic neurobiological and molecular mechanisms. Over the past 2
years of support, MH59803 studies moved "from bench-to-bedside," focusing on dopamine (DA)
agonist effects on PPI and neurocognition in HS, and their regulation by genes identified in
cross-species studies. These studies detected biological markers that predict PPI-enhancing
and pro-cognitive effects of the DA releaser, amphetamine (AMPH) in humans, leading to
specific predictions of AMPH effects on PPI, neurocognition and Targeted Cognitive Training
in SZ/SZA patients. If confirmed in the present application, these predictions could help
transform therapeutic approaches to SZ/SZA. This renewal application of MH59803 thus reflects
a logical progression of studies at systems and molecular levels, translated first to HS, and
now to potentially transformative therapeutic models in SZ/SZA patients.
MH59803 demonstrated that AMPH (20 mg p.o.) significantly increased PPI and neurocognitive
performance (MATRICS Consensus Cognitive Battery; MCCB) in HS characterized by specific
performance-based or genetic biomarkers, including the val/val genotype for the rs4680
polymorphism of catechol-O-methyltransferase (COMT). Mechanistically-informative results were
detected in studies of AMPH effects on PPI in rats with high vs. low brain regional Comt
expression. Together with several reports of improved neurocognition and no adverse effects
of acute or sustained AMPH administration to antipsychotic (AP)-medicated SZ/SZA patients,
MH59803 findings provide a strong rationale for the next goal of this application: to test
the potential utility of AMPH in a paradigm of biomarker-informed "PACTs". This "next step"
is highly innovative - never previously reported, or perhaps even attempted - and consistent
with National Institute of Mental Health (NIMH) objectives, directly challenges existing
models for SZ/SZA therapeutics. Investigators will determine whether a test dose of 10-20 mg
AMPH p.o. administered to biomarker-identified, AP-medicated SZ/SZA patients generates
predicted increases in PPI, MCCB performance, and sensory discrimination learning in a
Targeted Cognitive Training (TCT) module. In total, Investigators will leverage knowledge
generated through converging cross-species studies in MH59803, to directly advance scientific
and clinical domains, by testing the effects of a pro-cognitive drug on neurophysiological
and neurocognitive performance, and Targeted Cognitive Training, in biomarker-stratified
subgroups of SZ/SZA patients.
Aim: To assess acute effects of AMPH (0, 10 and 20 mg po) on PPI, neurocognition and
computerized TCT in AP-medicated SZ/SZA patients. Hypothesis: PPI- and MCCB-enhancing effects
of AMPH seen previously in HS will also be detected in SZ/SZA patients, as will TCT-enhancing
effects of AMPH. Prediction: In a within-subject, placebo-controlled, randomized design, AMPH
(10 and/or 20 mg po) will increase PPI and enhance MCCB and TCT performance in medicated
SZ/SZA patients, particularly among those characterized by low basal performance levels
and/or the val/val rs4680 COMT polymorphism. Concurrent HS testing will confirm (20 mg) and
extend (10 mg) findings of AMPH effects on PPI and neurocognition, and help interpret
findings in SZ/SZA patients.
In all participants, the aim to assess acute effects of 10 mg po dextroamphetamine (AMPH) on
Prepulse Inhibition (PPI), neurocognition MATRICS: Consensus Cognitive Battery; MCCB, and
computerized Targeted Cognitive Training (TCT).
Hypothesis: AMPH will enhance:
1. PPI
2. neurocognition (MCCB performance)
3. computerized TCT performance in biomarker-identified SZ/SZA patients.
4. The PPI and MCCB-enhancing effects of AMPH seen previously in HS will also be detected
in SZ/SZA patients, as will TCT-enhancing effects of AMPH.
Prediction: In a within-subject, placebo-controlled, randomized design, AMPH (10 and/or 20 mg
po) will increase PPI and enhance MCCB and TCT performance in medicated SZ/SZA patients,
particularly among those characterized by low basal performance levels and/or the val/val
rs4680 COMT polymorphism. Concurrent HS testing will confirm (20 mg) and extend (10 mg)
findings of AMPH effects on PPI and neurocognition, and help interpret findings in SZ/SZA
patients.
performance (MATRICS Consensus Cognitive Battery; MCCB) in HS characterized by specific
performance-based or genetic biomarkers, including the val/val genotype for the rs4680
polymorphism of catechol-O-methyltransferase (COMT). Mechanistically-informative results were
detected in studies of AMPH effects on PPI in rats with high vs. low brain regional Comt
expression. Together with several reports of improved neurocognition and no adverse effects
of acute or sustained AMPH administration to antipsychotic (AP)-medicated SZ/SZA patients,
MH59803 findings provide a strong rationale for the next goal of this application: to test
the potential utility of AMPH in a paradigm of biomarker-informed "PACTs". This "next step"
is highly innovative - never previously reported, or perhaps even attempted - and consistent
with National Institute of Mental Health (NIMH) objectives, directly challenges existing
models for SZ/SZA therapeutics. Investigators will determine whether a test dose of 10-20 mg
AMPH p.o. administered to biomarker-identified, AP-medicated SZ/SZA patients generates
predicted increases in PPI, MCCB performance, and sensory discrimination learning in a
Targeted Cognitive Training (TCT) module. In total, Investigators will leverage knowledge
generated through converging cross-species studies in MH59803, to directly advance scientific
and clinical domains, by testing the effects of a pro-cognitive drug on neurophysiological
and neurocognitive performance, and Targeted Cognitive Training, in biomarker-stratified
subgroups of SZ/SZA patients.
Aim: To assess acute effects of AMPH (0, 10 and 20 mg po) on PPI, neurocognition and
computerized TCT in AP-medicated SZ/SZA patients. Hypothesis: PPI- and MCCB-enhancing effects
of AMPH seen previously in HS will also be detected in SZ/SZA patients, as will TCT-enhancing
effects of AMPH. Prediction: In a within-subject, placebo-controlled, randomized design, AMPH
(10 and/or 20 mg po) will increase PPI and enhance MCCB and TCT performance in medicated
SZ/SZA patients, particularly among those characterized by low basal performance levels
and/or the val/val rs4680 COMT polymorphism. Concurrent HS testing will confirm (20 mg) and
extend (10 mg) findings of AMPH effects on PPI and neurocognition, and help interpret
findings in SZ/SZA patients.
In all participants, the aim to assess acute effects of 10 mg po dextroamphetamine (AMPH) on
Prepulse Inhibition (PPI), neurocognition MATRICS: Consensus Cognitive Battery; MCCB, and
computerized Targeted Cognitive Training (TCT).
Hypothesis: AMPH will enhance:
1. PPI
2. neurocognition (MCCB performance)
3. computerized TCT performance in biomarker-identified SZ/SZA patients.
4. The PPI and MCCB-enhancing effects of AMPH seen previously in HS will also be detected
in SZ/SZA patients, as will TCT-enhancing effects of AMPH.
Prediction: In a within-subject, placebo-controlled, randomized design, AMPH (10 and/or 20 mg
po) will increase PPI and enhance MCCB and TCT performance in medicated SZ/SZA patients,
particularly among those characterized by low basal performance levels and/or the val/val
rs4680 COMT polymorphism. Concurrent HS testing will confirm (20 mg) and extend (10 mg)
findings of AMPH effects on PPI and neurocognition, and help interpret findings in SZ/SZA
patients.
Inclusion Criteria:
- 18-55 years old:
- Drug Free (No recreational/street drugs)
- Diagnosis of Schizophrenia or Schizoaffective Disorder, Depressed Type
- Must be stable on antipsychotic medication for at least 1 month
- Any medications other than antipsychotic medications need to be stable for at least 1
week
Exclusion Criteria:
- Dominant hand injury
- Hearing impairment at 40 dB
- Irregular menstrual cycle or cycle is no within in 25-35 days (menopausal is eligible)
- EKG, conduction abnormalities confirmed by cardiologist
- Reading component of Wide Range Achievement Test 4 (WRAT4) Score less than 70
- Any serious illness, including: Insulin-dependent diabetes, HIV, AIDS, cancer, stroke,
heart attack, uncontrolled hypothyroidism
- Sleep apnea
- A diagnosis of epilepsy or history of seizures with loss of consciousness
- Open/closed head injury with loss of consciousness greater than 1 minute at any time
in the lifetime
- Blood pressure: Systolic Blood Pressure < 90 or > 160, Diastolic Blood Pressure < 45
or > 95
- Heart Rate < 55 or > 110
- Current use of Dexatrim or drugs containing phenylephrine (eligible if not used for at
least 72 hours prior to participation)
- Current use of St. John's Wort, Milk Thistle (eligible if for at least 1 month)
- Self report of any illicit drug use within the last 30 days
- Positive urine toxicology
- Self-report of any use of ecstasy, lysergic acid diethylamide (LSD), mushrooms, gamma
hydroxybutyrate (GHB), ketamine, phencyclidine (PCP), heroin or any intravenous-drugs
within past year
- If there is a history of substance abuse/addiction, participant must be in remission
for at least 6 months
- Within 1 month of recent psychiatric hospitalization
- Current mania
- Dementia/Alzheimer's diagnosis
- Mania episode meeting criteria outlined in the MINI-International Neuropsychiatric
Interview Plus 6.0 (M.I.N.I. plus 6.0) anytime in the lifetime (hypomania/Bipolar II
eligible)
We found this trial at
1
site
San Diego, California 92103
Principal Investigator: Neal R. Swerdlow, M.D., Ph.D.
Phone: 619-543-3093
Click here to add this to my saved trials
